Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where I. Guix is active.

Publication


Featured researches published by I. Guix.


International Journal of Radiation Oncology Biology Physics | 2010

Exeresis and Brachytherapy as Salvage Treatment for Local Recurrence After Conservative Treatment for Breast Cancer: Results of a Ten-Year Pilot Study

B. Guix; Jose A. Lejarcegui; J. Tello; Gabriel Zanón; I. Henriquez; Fernando Finestres; Antonio Martínez; Jaume Fernandez-Ibiza; Luis Quinzaños; Pau Palombo; Xavier Encinas; I. Guix

PURPOSE To analyze the long-term results of a pilot study assessing excision and brachytherapy as salvage treatment for local recurrence after conservative treatment of breast cancer. METHODS AND MATERIALS Between December 1990 and March 2001, 36 patients with breast-only recurrence less than 3 cm in diameter after conservative treatment for Stage I or II breast carcinoma were treated with local excision followed by high-dose rate brachytherapy implants (30 Gy in 12 fractions over a period of 5 days). No patient was lost to follow-up. Special attention was paid to local, regional, or distant recurrences; survival; cosmesis; and early and late side effects. RESULTS All patients completed treatment. During follow-up (range, 1-13 years), 8 patients presented metastases (2 regional and 6 distant) as their first site of failure, 1 had a differed local recurrence, and 1 died of the disease. Actuarial results at 10 years were as follows: local control, 89.4%; disease-free survival, 64.4%; and survival, 96.7%. Cosmetic results were satisfactory in 90.4%. No patient had Grade 3 or 4 early or late complications. Of the 11 patients followed up for at least 10 years, all but 1 still had their breast in place at the 10-year stage. CONCLUSIONS High-dose rate brachytherapy is a safe, effective treatment for small-size, low-risk local recurrence after local excision in conservatively treated patients. The dose of 30 Gy of high-dose rate brachytherapy (12 fractions over a period of 5 days twice daily) was well tolerated. The excellent results support the use of breast preservation as salvage treatment in selected patients with local recurrence after conservative treatment for breast cancer.


Journal of Clinical Oncology | 2015

Whole-breast hypofractionated IMRT and brachytherapy boost after conservative surgery for breast cancer: Early results of a prospective non-randomised trial.

B. Guix; Ivan Garcia; I. Guix; Juan Antonio Lejarcegui; J. Tello; Miquel Prats; Luis Quinzaños; Joel Mases; Manel Algara; Josep Maria Sole Monne; Teresa Guix

46 Background: To report early results obtained in a prospective group of patients (pts) treated with whole breast IMRT radiotherapy plus a brachytherapy boost to the tumor bed after conservative surgery, given either with hypofractionated or normofractionated radiotherapy. METHODS Between 12/2008 and 06/2014, 829 pts with <4cm, N0-2 breast cancers treated with conservative surgery were assigned to enter the study. Pts were offered to be treated either with IMRT hypofrationated whole breast and lymphnode areas (if needed) radiotherapy 42.6 Gy (266cGyx16 fractions) plus a 7 Gy boost to the tumor bed, (hypofractionated group) or IMRT normofractionated 50 Gy (200cGyx25) to the whole breast and lymphatic areas (when needed) plus 16 Gy brachytherapy boost (200cGyx8 fractions) (normofractionated group). Treatment assignation was done according to the patients preference or, if none, were randomly assigned to have both groups uniformly balanced. During treatment and follow-up special attention was taken to early and late side-effects, breast fibrosis, arm lymphedema, skin reaction, patient satisfaction and local, regional and distant disease control. RESULTS A total of 309 pts were included in the hypofractionated group and 520 in the normofractionated group. All patients completed treatment. Pts were evaluated weekly during treatment and every 3 months for the first 2 years of follow-up and in a yearly basis after. Photographs were taken at each visit. SOMA-LENT scales were used in every visit. For quality of life EORTC QLQ-C30 plus the BR-15 module were used. No pts had adverse side-effect that required treatment ending in any group. In the hypofractionated group, there were 1 LR, 1 M1 and 1 death due to the disease. In the normofractionated group there were 12 LR, 7 M1 and 4 patients died due to the disease. CONCLUSIONS Hypofractionated IMRT to the whole breast followed by a 1 fraction HDR breast implant was a safe and effective method of treatment for early breast cancer treated with conservative surgery, even in those patients N+ in which the supraclavicular fossa was included in the treatment fields. Pts satisfaction was greater in the hypofractionated group.


Journal of Clinical Oncology | 2011

Accelerated partial breast brachytherapy after lumpectomy as salvage treatment for local recurrences after conservative treatment of breast cancer: Eighteen-year results of a nonrandomized comparison with mastectomy.

B. Guix; J. A. Lejarcegui; J. Tello; I. Guix; G. Zanon; Luis Quinzaños; P. Palombo; J. M. Del-Campo; G. Galdon; M. Espino; A. Milla

109 Background: To report the long-term results in a prospective group of patients (pts) treated for local recurrence after conservative treatment of breast cancer by a second conservative surgery or by total mastectomy. METHODS Between 12/1990 and 10/2004, 85 pts with <3 cm, low-risk local recurrence after conservative treatment for breast cancer were offered total mastectomy. 48 of them refused it and were treated by a second lumpectomy followed by HDR brachytherapy implant to the tumor bed+margin. 30 Gy in 12 fractions in 5 days were given. Pts treated by mastectomy had no further radiotherapy. Postmenopausal pts with negative receptors had no systemic tx. The rest of the pts had chemo or hormones. No pts were lost for follow-up. RESULTS All pts completed treatment. During the 17-year, 1-year minimum follow-up, in the second conservative group there were 8 pts who had regional (2 pts) or distant metastases (6 pts) as their first site of failure. Three of them experienced a differed local recurrence and 1 died from the disease. In the total mastectomy group, there were 2 local recurrences, 1 regional recurrence, and 5 distant metastases as first site of failure. One patient died from the disease. Actuarial results at 17-year for second conservative and total mastectomy were respectively: local control 84.2%-71.7%; disease free survival 65.4%-63.8%; and survival 90.7% and 88.2%. Cosmetic results were satisfactory in 89.4% treated conservatively. No patient experienced arm edema or grade 3-4 early or late complications. Between the 14 pts that were followed-up for at least 10-years, 13 of them were with their breast still in place. CONCLUSIONS Second conservative treatment by HDR brachytherapy was a safe and effective method of treatment for small-size, low-risk, local recurrence after local excision in conservatively treated pts. APBI with wide margins probed to be enough treatment, without significant side-effects in previously intesively irradiated patients. Lumpectomy and partial breast brachytherapy can be conidered the treatment of choice in selected patients with low-risk recurrent breast tumors.


International Journal of Radiation Oncology Biology Physics | 2010

Partial Breast Brachytherapy after Lumpectomy as Salvage Treatment of Local Recurrences after Conservative Treatment of Breast Cancer: Eighteen-year Results of a Non-randomized Comparison with Mastectomy

B. Guix; Jose A. Lejarcegui; J. Tello; Gabriel Zanón; J. Del-Campo; Diego Rubio; P. Palombo; A. Milla; I. Guix; G. Galdon

Purpose/Objective(s): To report the long term results obtained in a prospective group of patients (pts) treated for local recurrence after conservative treatment of breast cancer treated by a second conservative surgery or by total mastectomy. Materials/Methods: Between 12/1990 and 10/2004, 85 patients with <3cm, low-risk local recurrence after conservative treatment for breast cancer were offered total mastectomy. 48 of them refused it and were treated by a second lumpectomy followed by HDR brachytherapy implant to the tumor bed plus a 3 cm margin. 30 Gy in 12 fractions in 5 days were given. Patients treated by mastectomy had no further radiotherapy treatment. Postmenopausal patients with negative receptors had no systemic treatment. The rest of the patients had chemo or hormonal treatment. No patient was lost for follow-up. Results: All patients completed treatment. During the 17-year, 1-year minimum follow-up, in the 2nd conservative group there were 8 pts who had regional (2 pts) or distant metastases (6 pts) as their first site of failure. 3 of them experienced a differed local recurrence and 1 died from the disease. In the total mastectomy group, there were 2 local recurrences, 1 regional recurrence and 5 distant metastases as first site of failure. One patient died from the disease. Actuarial results at 17-year for 2nd conservative and total mastectomy were respectively: local control 84.2% 71.7%; disease free survival 65.4%-63.8%; and survival 90.7% and 88.2%. Cosmetic results were satisfactory in 89.4 % treated conservatively. No patient experienced arm edema or grade 3-4 early or late complications. Between the 14 pts that were followed-up for at least 10-years, 13 of them were with their breast still in place. Conclusions: Second conservative treatment by HDR brachytherapy was a safe and effective method of treatment for small-size, lowrisk, local recurrence after local excision in conservatively treated patients. Partial breast irradiation with wide margins probed to be enough treatment, without significant side-effects in previously intesively irradiated patients. Lumpectomy and partial breast brachytherapy can be conidered the treatment of choice in selected patients with low-risk recurrent breast tumors.


International Journal of Radiation Oncology Biology Physics | 2010

Treatment of Intermediate-or High-risk Prostate Cancer by Dose Escalation with High-dose 3D-conformal Radiotherapy (HD-3D-CRT) or Low-dose 3D-conformal Radiotherapy Plus HDR Brachytherapy (LD-3D-CRT+HDR-B): Early Results of a Prospective Comparative Trial

B. Guix; J. Bartrina; J. Tello; J. Solé; Luis Quinzaños; T. Lacorte; J. Fernández; C. León; I. Guix; G. Galdon


Journal of Clinical Oncology | 2018

Dose escalation with high-dose-3D-conformal/IMRT (HD-3D-CRT/IMRT) compared with low-dose 3D-conformal/IMRT plus HDR brachytherapy (LD-3D-CRT/IMRT+HDR-B) for intermediate- or high-risk prostate cancer: Disease control, survival, and toxicity.

I. Guix; Jose Maria Bartrina; J. Tello; Ivan Garcia; Luis Quinzaños; T. Lacorte; Teresa Guix; B. Guix


Journal of Clinical Oncology | 2016

Hypofractionated whole breast IMRT and brachytherapy boost after conservative surgery for breast cancer: Early results of a prospective non-randomised trial.

I. Guix; Ivan Garcia; Diego Alcaraz; Sandra Rubio Diez; Albert Abad Esteve; Jose Maria Del Campo; Jordi Antoni; Saioa Gorostidi; Miquel Prats; Luis Quinzaños; Teresa Guix; J. Tello; B. Guix


Brachytherapy | 2016

Dose Escalation with High-Dose-3D-Conformal/IMRT (HD-3D-CRT/IMRT) Compared with Low-Dose 3D-Conformal/IMRT Plus HDR Brachytherapy (LD-3D-CRT/IMRT+HDR-B) for Intermediate- or High-Risk Prostate Cancer: Higher Disease Control and Survival with Lower Toxicity

B. Guix; Jose Maria Bartrina; I. Guix; J. Tello; I. Henriquez; Luis Quinzaños; Ivan Garcia; Joel Mases; Teresamaria Lacorte; Guillermo Galdon; Teresa Guix


International Journal of Radiation Oncology Biology Physics | 2013

Quality of Life After IMRT or IMRT+HDR Brachytherapy for Intermediate- or High-Risk Prostate Cancer: 8-Year Results of a Prospective Trial

B. Guix; T. Lacorte; J. Bartrina; J. Tello; I. Guix; G. Galdon; M. Espino; T. Guix


International Journal of Radiation Oncology Biology Physics | 2012

Dose Escalation With High-dose 3D-Conformal (HD-3D-CRT) or Low-dose 3D-Conformal Radiation Therapy (LD-3D-CRT+HDR-B) for Intermediate- or High-Risk Prostate Cancer: Higher Disease Control and Survival With Lower Toxicity

B. Guix; J. Bartrina; J. Tello; I. Henriquez; Luis Quinzaños; T. Lacorte; I. Guix; G. Galdon; M. Espino

Collaboration


Dive into the I. Guix's collaboration.

Top Co-Authors

Avatar

B. Guix

University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

J. Tello

University of Barcelona

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

I. Henriquez

University of Barcelona

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Pau Palombo

University of Barcelona

View shared research outputs
Researchain Logo
Decentralizing Knowledge